Literature DB >> 31032168

Synthesis and biological activity of 4-amino-3-chloro-1H-pyrrole-2,5-diones.

Halyna M Kuznietsova1, Vasyl V Hurmach1, Andriy V Bychko2, Olena I Tykhoniuk1, Demyd S Milokhov1, Olga V Khilya1, Yulian M Volovenko1, Volodymyr K Rybalchenko1.   

Abstract

4-Amino-3-chloro-1H-pyrrole-2,5-dione derivatives were designed and synthesized as potential tyrosine kinase inhibitors. One of them has been shown to inhibit growth of cancer cell lines and in vivo tumors. To determine the impact of side groups on biological activity the ability of different 4-amino-3-chloro-1H-pyrrole-2,5-diones to interact with ATP-binding domains of growth factor receptors and with model cell membranes were aimed to be discovered. The methods of molecular docking, short-molecular dynamics (in silico) and non-steady cyclic current-voltage characteristics (in vitro) were used. Five 4-amino-3-chloro-1H-pyrrole-2,5-diones were synthesized from 3,4-dichloro-1H-pyrrole-2,5-diones. All of them demonstrated the potential ability to form complexes with ATP-binding domains of EGFR and VEGFR2. These complexes were more stable compared to those with ANP. 4-Amino-3-chloro-1H-pyrrole-2,5-diones while interact with different bilayer lipid membranes caused an increase of their specific conductance and electric capacity, demonstrating the certain disturbance in lipid packing. Obtained data allowed us to suggest that proposed chemicals can interact with the surface of lipid bilayer, do likely intercalate into the membrane and form stable complexes with EGFR and VEGFR2. So, the prospect of developed chemicals to be effective EGFR and VEGFR2 inhibitors and therefore realize antitumor activity was concluded.

Entities:  

Keywords:  4-Amino-3-chloro-1H-pyrrole-2; 5-Dione derivatives; Bilayer lipid membranes; Cyclic current–voltage characteristics; EGFR; VEGFR2

Year:  2019        PMID: 31032168      PMCID: PMC6458214          DOI: 10.1007/s40203-019-0051-2

Source DB:  PubMed          Journal:  In Silico Pharmacol        ISSN: 2193-9616


  17 in total

Review 1.  [New antibodies in cancer treatment].

Authors:  B C Pestalozzi; A Knuth
Journal:  Praxis (Bern 1994)       Date:  2004-09-22

2.  Handling side-effects of targeted therapies: safety of targeted therapies in solid tumours.

Authors:  E Elez; T Macarulla; J Tabernero
Journal:  Ann Oncol       Date:  2008-09       Impact factor: 32.976

3.  QXP: powerful, rapid computer algorithms for structure-based drug design.

Authors:  C McMartin; R S Bohacek
Journal:  J Comput Aided Mol Des       Date:  1997-07       Impact factor: 3.686

4.  Tyrosine kinase inhibitors: Multi-targeted or single-targeted?

Authors:  Fleur Broekman; Elisa Giovannetti; Godefridus J Peters
Journal:  World J Clin Oncol       Date:  2011-02-10

Review 5.  Patient-reported outcomes in the evaluation of toxicity of anticancer treatments.

Authors:  Massimo Di Maio; Ethan Basch; Jane Bryce; Francesco Perrone
Journal:  Nat Rev Clin Oncol       Date:  2016-01-20       Impact factor: 66.675

Review 6.  Properties of FDA-approved small molecule protein kinase inhibitors.

Authors:  Robert Roskoski
Journal:  Pharmacol Res       Date:  2019-03-13       Impact factor: 7.658

Review 7.  Targeted therapies: a new generation of cancer treatments.

Authors:  David E Gerber
Journal:  Am Fam Physician       Date:  2008-02-01       Impact factor: 3.292

8.  [Effect of dihydropyrrol and maleimide derivatives on the state of the liver and colon in normal rats and those with colorectal carcinogenesis induced by dimethylhydrazine].

Authors:  H M Kuznietsova; O V Lynchak; M O Danylov; I P Kotliar; V K Rybal'chenko
Journal:  Ukr Biokhim Zh (1999)       Date:  2013 May-Jun

Review 9.  New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.

Authors:  Frank Kroschinsky; Friedrich Stölzel; Simone von Bonin; Gernot Beutel; Matthias Kochanek; Michael Kiehl; Peter Schellongowski
Journal:  Crit Care       Date:  2017-04-14       Impact factor: 9.097

10.  Effects of 5-Amyno-4-(1,3-benzothyazol-2-yn)-1-(3-methoxyphenyl)-1,2-dihydro-3H-pyrrol-3-one Intake on Digestive System in a Rat Model of Colon Cancer.

Authors:  Halyna M Kuznietsova; Valentyna K Luzhenetska; Iryna P Kotlyar; Volodymyr K Rybalchenko
Journal:  ScientificWorldJournal       Date:  2015-10-04
View more
  1 in total

1.  Suppression of systemic inflammation and signs of acute and chronic cholangitis by multi-kinase inhibitor 1-(4-Cl-benzyl)-3-chloro-4-(CF3-phenylamino)-1H-pyrrole-2,5-dione.

Authors:  Halyna Kuznietsova; Iryna Byelinska; Natalia Dziubenko; Oksana Lynchak; Demyd Milokhov; Olga Khilya; Nataliya Finiuk; Olga Klyuchivska; Rostyslav Stoika; Volodymyr Rybalchenko
Journal:  Mol Cell Biochem       Date:  2021-04-01       Impact factor: 3.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.